In multiple myeloma cells, sensitivity to bortezomib treatment was associated with higher expression of ATF4 and loss of its expression lead to lower levels of Noxa, CHOP and DR5 (Narita et al., 2015). This evidence concerns the gene ATF4 and plasma cell myeloma.